Antisense suppression of donor splice site mutations in the dystrophin gene transcript

We describe two donor splice site mutations, affecting dystrophin exons 16 and 45 that led to Duchenne muscular dystrophy (DMD), through catastrophic inactivation of the mRNA. These gene lesions unexpectedly resulted in the retention of the downstream introns, thereby increasing the length of the dystrophin mRNA by 20.2 and 36 kb, respectively. Splice‐switching antisense oligomers targeted to exon 16 excised this in‐frame exon and the following intron from the patient dystrophin transcript very efficiently in vitro, thereby restoring the reading frame and allowing synthesis of near‐normal levels of a putatively functional dystrophin isoform. In contrast, targeting splice‐switching oligomers to exon 45 in patient cells promoted only modest levels of an out‐of‐frame dystrophin transcript after transfection at high oligomer concentrations, whereas dual targeting of exons 44 and 45 or 45 and 46 resulted in more efficient exon skipping, with concomitant removal of intron 45. The splice site mutations reported here appear highly amenable to antisense oligomer intervention. We suggest that other splice site mutations may need to be evaluated for oligomer interventions on a case‐by‐case basis.

[1]  Kevin M Flanigan,et al.  The Muscular Dystrophies , 1999, Seminars in Neurology.

[2]  E. Buratti,et al.  Complexities of 5'splice site definition: Implications in clinical analyses , 2012, RNA biology.

[3]  Alastair R W Kerr,et al.  Co-transcriptional degradation of aberrant pre-mRNA by Xrn2 , 2012, The EMBO journal.

[4]  B. Wong,et al.  Multiple exon skipping strategies to by-pass dystrophin mutations , 2012, Neuromuscular Disorders.

[5]  R. Kole,et al.  Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching , 2011, BMC Medical Genetics.

[6]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[7]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[8]  N. Bresolin,et al.  Clinical and molecular characterization of a cohort of patients with novel nucleotide alterations of the Dystrophin gene detected by direct sequencing , 2011, BMC Medical Genetics.

[9]  F. Muntoni,et al.  Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations , 2010, Neuromuscular Disorders.

[10]  H. Moulton,et al.  Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. , 2010, Biochimica et biophysica acta.

[11]  Y. Takeshima,et al.  P4.03 Mutation spectrum of the dystrophin gene in 456 Duchenne/Becker muscular dystrophy cases from one Japanese referral center , 2010, Neuromuscular Disorders.

[12]  Zhujun Zhang,et al.  Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center , 2010, Journal of Human Genetics.

[13]  J. Rubio,et al.  Splicing, cis genetic variation and disease. , 2009, Biochemical Society transactions.

[14]  I. Graham,et al.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study , 2009, The Lancet. Neurology.

[15]  R. Kole,et al.  Peptide‐Morpholino Conjugate: A Promising Therapeutic for Duchenne Muscular Dystrophy , 2009, Annals of the New York Academy of Sciences.

[16]  F. Muntoni,et al.  Rational design of antisense oligomers to induce dystrophin exon skipping. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  D. Baralle,et al.  Missed threads , 2009, EMBO reports.

[18]  Akinori Nakamura,et al.  Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs , 2009, Annals of neurology.

[19]  G. van Ommen,et al.  Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations , 2009, Human mutation.

[20]  P. Iversen,et al.  Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  R. Finkel,et al.  DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy , 2008, Annals of neurology.

[22]  Johan T den Dunnen,et al.  Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.

[23]  I. Graham,et al.  Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. , 2007, Human gene therapy.

[24]  D. A. Stein,et al.  Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. , 2007, Biochemical Society transactions.

[25]  P. Iversen,et al.  Bmc Molecular Biology Antisense Oligonucleotide Induced Exon Skipping and the Dystrophin Gene Transcript: Cocktails and Chemistries , 2022 .

[26]  Adrian R. Krainer,et al.  Aberrant 5′ splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization , 2007, Nucleic acids research.

[27]  P. Palange,et al.  From the authors , 2007, European Respiratory Journal.

[28]  J. Hampe,et al.  Single base‐pair substitutions in exon–intron junctions of human genes: nature, distribution, and consequences for mRNA splicing , 2007, Human mutation.

[29]  M. Schwartz,et al.  Deletion of exon 16 of the dystrophin gene is not associated with disease , 2007, Human mutation.

[30]  P. Iversen,et al.  Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD , 2006, Gene Therapy.

[31]  I. Vořechovský,et al.  Aberrant 3′ splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization , 2006, Nucleic acids research.

[32]  S. Wilton,et al.  Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide , 2006, The journal of gene medicine.

[33]  D. Baralle,et al.  Splicing in action: assessing disease causing sequence changes , 2005, Journal of Medical Genetics.

[34]  Y. Takeshima,et al.  A G-to-A transition at the fifth position of intron-32 of the dystrophin gene inactivates a splice-donor site both in vivo and in vitro. , 2005, Molecular genetics and metabolism.

[35]  I. Férnandez-Cadenas,et al.  Splicing mosaic of the myophosphorylase gene due to a silent mutation in McArdle disease , 2003, Neurology.

[36]  C. Mann,et al.  Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy , 2002, The journal of gene medicine.

[37]  S. Corti,et al.  A novel splice site mutation (3157+1G>T) in the dystrophin gene causing total exon skipping and DMD phenotype , 2001, Human mutation.

[38]  C. Mann,et al.  Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. G. Cusella De Angelis,et al.  High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. , 1998, The Journal of clinical investigation.

[40]  Y. Takeshima,et al.  Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. , 1995, The Journal of clinical investigation.

[41]  T. Vulliamy,et al.  Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. , 1993, American journal of human genetics.

[42]  Z. Dominski,et al.  Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Cooper,et al.  The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: Causes and consequences , 1992, Human Genetics.

[44]  R. Bartlett,et al.  An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. , 1992, Genomics.

[45]  C. Harwood,et al.  Dystrophin in skeletal muscle I. Western blot analysis using a monoclonal antibody , 1989, Journal of the Neurological Sciences.

[46]  K. Bushby,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. , 2011, Lancet.

[47]  S. Wilton,et al.  The influence of antisense oligonucleotide length on dystrophin exon skipping. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  Y. Takeshima,et al.  Heterogous Dystrophin mRNA Produced by a Novel Splice Acceptor Site Mutation in Intermediate Dystrophinopathy , 2003, Pediatric Research.

[49]  G. van Ommen,et al.  Advances in Duchenne muscular dystrophy gene therapy , 2003, Nature reviews. Genetics.

[50]  M Bobrow,et al.  Searching for the 1 in 2,400,000: A review of dystrophin gene point mutations , 1994, Human mutation.

[51]  W. King,et al.  Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy. , 1993, Human molecular genetics.